Based on the provided paper content, I will answer each question systematically.

"""
Question: 1101

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance. In the present study, we reported a molecular epidemi- ological investigation in a subset of 451 HIV-1 seropositive individuals during 2004 to 2008 in Zhejiang.

Rationale: The paper explicitly states it is presenting a new study and reporting on an investigation of data collected from 2004 to 2008. This indicates the data being reported is from the authors' own research and has not been published previously in this context.

Answer: Yes
"""

"""
Question: 1102

Evidence: Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples, respectively (Supplementary files 1 and 2). The HIV sequences are accessible in GenBank from KJ613998 to KJ614226 (Pol) and from KJ613666to KJ613997 (Gag).

Rationale: The paper directly states that specific HIV gene fragments (*gag* and *pol*) were amplified and sequenced from patient samples. It also provides the GenBank accession number ranges for these sequences, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance. A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008.

Rationale: The paper describes a molecular epidemiological surveillance study involving the collection and sequencing of patient samples. There is no mention of any in vitro passage experiments being conducted on viruses in a laboratory setting.

Answer: No
"""

"""
Question: 1104

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance. Sequence analyses indicated that three HIV-1 subtypes (B/B', C, and G), five circulating recombination forms (CRF01_AE, CRF07_BC, CRF08_BC, CRF02_AG, and CRF06_CPX), and some novel recombinant strains were detected.

Rationale: The paper mentions "drug resistance" in the context of the surveillance program, but the results section focuses exclusively on genotypic analysis (subtyping and identifying recombinant strains). There is no data presented on in vitro susceptibility testing (e.g., IC50 values) against antiretroviral drugs.

Answer: No
"""

"""
Question: 2101

Evidence: The HIV sequences are accessible in GenBank from KJ613998 to KJ614226 (Pol) and from KJ613666to KJ613997 (Gag).

Rationale: The "Acknowledgments" section explicitly provides the GenBank accession number ranges for the sequenced *pol* and *gag* gene fragments obtained from the study participants.

Answer: Yes
"""

"""
Question: 2102

Evidence: The HIV sequences are accessible in GenBank from KJ613998 to KJ614226 (Pol) and from KJ613666to KJ613997 (Gag). A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008.

Rationale: The GenBank accession numbers provided are for sequences derived from patient samples collected for this surveillance study. The paper does not mention sequencing or using any established laboratory HIV isolates (like HXB2, which is used as a reference for nucleotide positions but not sequenced anew).

Answer: Yes
"""

"""
Question: 2103

Evidence: The HIV sequences are accessible in GenBank from KJ613998 to KJ614226 (Pol) and from KJ613666to KJ613997 (Gag).

Rationale: The paper provides two ranges of GenBank accession numbers: one set for the *pol* gene sequences (KJ613998 to KJ614226) and another set for the *gag* gene sequences (KJ613666 to KJ613997). It does not list individual numbers for each sequence.

Answer: KJ613998 to KJ614226 (Pol), KJ613666 to KJ613997 (Gag)
"""

"""
Question: 2202

Evidence: Sequence analyses indicated that three HIV-1 subtypes (B/B', C, and G), five circulating recombination forms (CRF01_AE, CRF07_BC, CRF08_BC, CRF02_AG, and CRF06_CPX), and some novel recombinant strains were detected. In this study, we observed 13 novel recombinant strains including CRF07-CRF08, CRF01-B, and CRF01- C.

Rationale: The paper reports on the subtypes and recombinant forms found but does not provide any lists of specific mutations (e.g., amino acid changes in the protease or reverse transcriptase genes) for individual sequenced isolates.

Answer: No
"""

"""
Question: 2301

Evidence: The epidemic characteristics of human immu- nodeficiency virus type 1 (HIV-1) in Zhejiang Province have not been systematically identified. This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008.

Rationale: The paper's title, abstract, and introduction consistently specify that the subject of the study is Human Immunodeficiency Virus Type 1 (HIV-1). There is no mention of HIV-2.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: CRF01_AE was the major strain, infecting 196 cases (43.5 %), and it was mainly distributed through heterosexual contact. Then, subtype B/B' (Thai-B) took second place, accounting for 17.9 %. The CRF07_BC and CRF08_BC strains accounted for 17.1 and 13.7 % infections, respectively. The rest strains (35 cases, 7.8 %) included CRF02_AG (8 cases), CRF06_CPX (2 case), subtype G (2 case), subtype C (10 cases), and 13 potentially novel recombinant strains.

Rationale: The "Results" section provides a detailed breakdown of the HIV-1 subtypes and Circulating Recombinant Forms (CRFs) identified in the study population.

Answer: CRF01_AE, B/B', CRF07_BC, CRF08_BC, CRF02_AG, CRF06_CPX, G, C, and novel recombinants (CRF07-CRF08, CRF01-B, CRF01-C)
"""

"""
Question: 2303

Evidence: The portion of the *gag* gene p17--p24 region (HXB2, 836--1507 nt) and the *pol* gene fragment (HXB2, 2147--3462 nt) were selected for PCR amplification and phylogenetic analyses. Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples, respectively.

Rationale: The "Materials and methods" section explicitly states which gene fragments were targeted for sequencing: a region of the *gag* gene and a fragment of the *pol* gene.

Answer: gag, pol
"""

"""
Question: 2304

Evidence: Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples, respectively (Supplementary files 1 and 2). In drug resistance surveillance, only pol gene was harvested.

Rationale: The paper confirms that *pol* gene sequences were obtained as part of the study, with 229 such sequences generated.

Answer: Yes
"""

"""
Question: 2401

Evidence: The 451 HIV-1-seropositive individuals were followed up by Zhejiang CDC during 2004--2008. Geographically, 57.6 % ( *n* = 260) of the HIV-1-positive patients were local residents from all 11 cities of the province. Except for the seven unknown cases, the remaining 40.8 % ( *n* = 184) originally came from the other 23 provinces of China, including Yunnan, Guangxi, Sichuan, Guizhou, Henan, Chongqing, Anhui, Jiangxi, and others.

Rationale: The paper specifies that samples were from individuals in or originating from Zhejiang Province, China. It also lists other Chinese provinces that contributed to the "floating population" cases.

Answer: Zhejiang Province, China; also individuals from other Chinese provinces including Yunnan, Guangxi, Sichuan, Guizhou, Henan, Chongqing, Anhui, and Jiangxi.
"""

"""
Question: 2402

Evidence: A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008 (Table 1 ). The 451 HIV-1-seropositive individuals were followed up by Zhejiang CDC during 2004--2008.

Rationale: The "Materials and methods" and "Results" sections consistently state that the samples were collected over the five-year period from 2004 to 2008.

Answer: 2004 to 2008
"""

"""
Question: 2502

Evidence: PCR products were purified using Qiagen gel extraction kit, and sequenced using an automated ABI 377 DNA Sequencer (Applied Biosystems).

Rationale: The ABI 377 DNA Sequencer is a platform that uses Sanger sequencing technology. The description of PCR product purification and sequencing on this instrument is characteristic of traditional Sanger sequencing methods.

Answer: Yes
"""

"""
Question: 2503

Evidence: PCR products were purified using Qiagen gel extraction kit, and sequenced using an automated ABI 377 DNA Sequencer (Applied Biosystems).

Rationale: The paper explicitly states that sequencing was performed using an ABI 377 DNA Sequencer, which is a Sanger sequencing platform. There is no mention of any Next-Generation Sequencing (NGS) technologies.

Answer: No
"""

"""
Question: 2504

Evidence: Viral RNA was extracted from patient plasma (140 μl) using QIAamp Viral RNA Mini kit (Qiagen, USA). HIV-1 cDNA was obtained through RT-PCR using the Takara One Step RNA PCR kit (Takara, China) and then subjected to nested polymerase chain reaction (PCR) for the amplification of *gag* and *pol* gene fragments.

Rationale: The methods describe bulk RNA extraction, RT-PCR, and nested PCR from patient plasma. There is no mention of a step where the PCR products were cloned into a vector prior to sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: Viral RNA was extracted from patient plasma (140 μl)... HIV-1 cDNA was obtained through RT-PCR... and then subjected to nested polymerase chain reaction (PCR) for the amplification of *gag* and *pol* gene fragments.

Rationale: The protocol describes standard RT-PCR and nested PCR, which amplify a mixture of templates from the viral population. There is no description of procedures specific to Single Genome Sequencing (SGS), such as endpoint dilution of the cDNA to ensure amplification from a single template molecule.

Answer: No
"""

"""
Question: 2506

Evidence: Viral RNA was extracted from patient plasma... HIV-1 cDNA was obtained through RT-PCR... and then subjected to nested polymerase chain reaction (PCR)... PCR products were purified... and sequenced.

Rationale: The sequencing was performed directly on the PCR products. The methods do not include a step for inserting the amplified DNA into a bacterial plasmid (cloning vector) for propagation and subsequent sequencing of individual clones.

Answer: No
"""

"""
Question: 2601

Evidence: Viral RNA was extracted from patient plasma (140 μl) using QIAamp Viral RNA Mini kit (Qiagen, USA).

Rationale: The paper explicitly states that viral RNA was extracted from patient plasma, which is the standard source material for sequencing replicating plasma virus.

Answer: Yes
"""

"""
Question: 2602

Evidence: The blood samples were separated into plasma and peripheral blood monocular cells (PBMC) and stored at −80 °C until use according to standard procedures.

Rationale: The paper states that PBMCs were collected and stored from the blood samples. However, the sequencing methods section only describes RNA extraction from plasma and subsequent RT-PCR. There is no mention of DNA extraction from PBMCs or amplification of proviral DNA.

Answer: No
"""

"""
Question: 2603

Evidence: A total of 451 HIV-1-positive patient samples were collected. Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples, respectively. Viral RNA was extracted from patient plasma.

Rationale: The paper states that viral RNA for sequencing was sourced from plasma. It reports that a total of 451 samples were collected, and from these, 332 *gag* and 229 *pol* sequences were successfully generated from plasma viral RNA.

Answer: 451 samples were intended for plasma virus sequencing; 332 yielded gag sequences and 229 yielded pol sequences.
"""

"""
Question: 2604

Evidence: The blood samples were separated into plasma and peripheral blood monocular cells (PBMC) and stored at −80 °C until use.

Rationale: While PBMCs were collected and stored, the methods for sequencing only describe using plasma as the source of viral RNA. There is no report of sequencing being performed on virus from the PBMC fraction.

Answer: 0
"""

"""
Question: 2605

Evidence: Viral RNA was extracted from patient plasma (140 μl) using QIAamp Viral RNA Mini kit (Qiagen, USA).

Rationale: Sequencing was performed on viral RNA extracted from plasma. Plasma virus represents actively replicating HIV, as opposed to the latent proviral reservoir in cells.

Answer: Yes
"""

"""
Question: 2606

Evidence: Viral RNA was extracted from patient plasma (140 μl) using QIAamp Viral RNA Mini kit (Qiagen, USA).

Rationale: The paper explicitly describes sequencing from plasma viral RNA. It does not mention DNA extraction from PBMCs or the amplification and sequencing of integrated proviral DNA.

Answer: No
"""

"""
Question: 2701

Evidence: Age: ≤18 ( *n* = 11, 2.4 %). Five cases were diagnosed as infection through vertical and mother-to-child (MTC) transmission.

Rationale: Table 1 shows that 11 individuals were aged 18 or younger. The results text also specifically mentions five cases of mother-to-child transmission, which inherently involves infants/children.

Answer: Yes
"""

"""
Question: 2702

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper describes a public health surveillance study, not a clinical trial. There is no mention of participants being enrolled in an interventional clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The study design is explicitly stated as surveillance-based. Since it was not a clinical trial, the question of whether all individuals were in one is not applicable.

Answer: No
"""

"""
Question: 3101

Evidence: A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008 (Table 1 ). The 451 HIV-1-seropositive individuals were followed up by Zhejiang CDC during 2004--2008.

Rationale: The paper clearly states that samples were obtained from 451 HIV-1 seropositive individuals for the purpose of the study.

Answer: 451
"""

"""
Question: 3102

Evidence: Totally, 332 *gag* and 229 *pol* gene fragments were amplified and sequenced from the 451 individual samples, respectively.

Rationale: While samples were obtained from 451 individuals, sequencing was not 100% successful. The paper reports that 332 *gag* sequences and 229 *pol* sequences were obtained from the 451 samples, meaning not every individual had both genes sequenced, and some may have failed sequencing altogether.

Answer: No
"""

"""
Question: 4101

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the ART treatment status of the 451 individuals from whom samples were taken. It is a surveillance study focusing on molecular epidemiology and subtypes, not on treatment history.

Answer: NA
"""

"""
Question: 4102

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the ART treatment status (naive or experienced) of the individuals in the study.

Answer: NA
"""

"""
Question: 4103

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: No information is provided regarding the ART history of the study participants. Therefore, it cannot be determined if sequences came from either ART-naive or ART-experienced individuals.

Answer: NA
"""

"""
Question: 4104

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not contain any data on which individuals were ART-naive.

Answer: NA
"""

"""
Question: 4105

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance. Data were collected using an interviewer-administered questionnaire. Demographic variables were collected including age, gender, ethnicity, transmission route, education, birth place, and current residence, etc.

Rationale: The list of collected demographic variables does not include ART history. The paper focuses on epidemiology and subtyping, not on treatment outcomes or resistance in the context of therapy.

Answer: No
"""

"""
Question: 4201

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: Although "drug resistance" is mentioned as part of the surveillance scope, the results and discussion sections only report on HIV-1 subtypes and recombinant forms. There is no data presented on the prevalence of transmitted drug resistance mutations.

Answer: No
"""

"""
Question: 4202

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any data on pretreatment HIV drug resistance (PDR), which is a form of transmitted drug resistance or resistance in ART-naive individuals. The results are focused solely on genetic subtypes.

Answer: No
"""

"""
Question: 4301

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on"""
Question: 4301

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the specific antiretroviral drug classes, or any drugs at all, received by the individuals in the study. The focus is on molecular epidemiology, not treatment.

Answer: NA
"""

"""
Question: 4302

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not contain any information about individuals receiving integrase inhibitors or any other specific class of antiretroviral drugs.

Answer: No
"""

"""
Question: 4303

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not contain any information about individuals receiving protease inhibitors or any other specific class of antiretroviral drugs.

Answer: No
"""

"""
Question: 4304

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the ART regimens of the individuals, so it is impossible to determine if they were all the same.

Answer: NA
"""

"""
Question: 4305

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the treatment history of the individuals, including whether they were naive to integrase strand transfer inhibitors (INSTIs).

Answer: NA
"""

"""
Question: 4403

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the number of ART regimens received by the individuals.

Answer: NA
"""

"""
Question: 4404

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the number of ART regimens received by the individuals.

Answer: NA
"""

"""
Question: 4405

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the ART regimens of the individuals, including the number of regimens they received.

Answer: NA
"""

"""
Question: 4406

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not provide any information on the ART regimens of the individuals, including whether they all received only one regimen.

Answer: NA
"""

"""
Question: 4501

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not mention the use of any specific antiretroviral drugs, including dolutegravir.

Answer: 0
"""

"""
Question: 4502

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not mention the use of any specific antiretroviral drugs, including darunavir.

Answer: 0
"""

"""
Question: 5101

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance. Sequence analyses indicated that three HIV-1 subtypes (B/B', C, and G), five circulating recombination forms (CRF01_AE, CRF07_BC, CRF08_BC, CRF02_AG, and CRF06_CPX), and some novel recombinant strains were detected.

Rationale: The results section reports on the genetic subtypes and recombinants found, but it does not report any data on the identification or count of drug resistance mutations in the studied individuals.

Answer: NA
"""

"""
Question: 5102

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any data on the presence of INSTI-resistance mutations or any other drug resistance mutations.

Answer: NA
"""

"""
Question: 5103

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any data on the presence of TDF-resistance mutations or any other drug resistance mutations.

Answer: NA
"""

"""
Question: 5104

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any specific drug resistance mutations, including those related to INSTIs.

Answer: NA
"""

"""
Question: 6101

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper focuses on genotypic analysis (sequencing and subtyping). There is no description of any phenotypic susceptibility tests being performed.

Answer: NA
"""

"""
Question: 6102

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any phenotypic susceptibility data, including IC50 or IC90 values.

Answer: No
"""

"""
Question: 6103

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any phenotypic susceptibility data, including IC50 fold-change values.

Answer: No
"""

"""
Question: 6104

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not describe the use of any phenotypic susceptibility assay, as this type of testing was not performed.

Answer: NA
"""

"""
Question: 6105

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report any data on viral replication capacity.

Answer: No
"""

"""
Question: 6106

Evidence: This study pre- sented a dynamic analysis of HIV-1 subtype variation in Zhejiang from 2004 to 2008, based on the surveillance of molecular epidemiology or drug resistance.

Rationale: The paper does not report phenotypic susceptibility testing for any antiretroviral drugs.

Answer: NA
"""

"""
Question: 7101

Evidence: A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008. Sequence analyses indicated that three HIV-1 subtypes (B/B', C, and G), five circulating recombination forms (CRF01_AE, CRF07_BC, CRF08_BC, CRF02_AG, and CRF06_CPX), and some novel recombinant strains were detected.

Rationale: The isolates described in the paper were obtained directly from patient samples through surveillance. There is no mention of any viruses being genetically engineered through site-directed mutagenesis.

Answer: No
"""

"""
Question: 7102

Evidence: The study was conducted in a cross-sectional and anonymous manner in all 11 cities, based on the surveillance of molecular epidemiology or drug resistance. A total of 451 HIV-1-positive patient samples were collected by local CDC staff from 2004 to 2008.

Rationale: The paper describes a study of viruses collected directly from patients. It does not describe any experiments involving the passage of viruses in cell culture in a laboratory setting.

Answer: No
"""